BMS-986213

BIOLOGICAL3 trials

Sponsors

Bristol-Myers Squibb

Conditions

Advanced Solid TumorsCancer of the StomachEsophagogastric JunctionGastric CancerNeoplasms by Site

Phase 1

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

CompletedNCT01968109

Bristol-Myers SquibbNeoplasms by Site

Start: 2013-11-05End: 2025-02-03Updated: 2026-01-06

A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors

CompletedNCT05134948

Bristol-Myers SquibbAdvanced Solid Tumors

Start: 2021-11-30End: 2025-10-24Updated: 2025-12-03

Phase 2

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

CompletedNCT03662659

Bristol-Myers SquibbCancer of the Stomach, Esophagogastric Junction, Gastric Cancer

Start: 2018-10-16End: 2024-01-18Updated: 2025-02-05

Related Papers

Randomized dose evaluation of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with advanced melanoma: Results from RELATIVITY-020.

Journal of Clinical Oncology2025-05-28

RELATIVITY-020: Intracranial (IC) activity of nivolumab + relatlimab (NIVO + RELA) in patients (pts) with PD-(L)1 refractory melanoma with melanoma brain metastases (MBM).

Journal of Clinical Oncology2025-05-28

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

Universität Zürich, ZORA2025-02-25

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

Journal for ImmunoTherapy of Cancer2025-02-014 citations

Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma

Journal of Clinical Investigation2023-01-3188 citations

1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types

Regular and Young Investigator Award Abstracts2022-11-011 citations

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature2022-10-26311 citations

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy

Cancer Immunology Research2022-08-1513 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis

JNCI Cancer Spectrum2020-12-0720 citations

CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

Journal of Clinical Oncology2019-05-2023 citations

Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.

Journal of Clinical Oncology2017-05-20238 citations